Rejected from JCI Insight? The 7 Best Journals to Submit Next

Source: Clarivate JCR 2024, publisher author pages (Cell Press, EMBO Press, PNAS, eLife, ASCI), accessed June 2026. APCs are list prices excluding tax and may be reduced by waivers.

1. Cell Reports Medicine. The cleanest step for a JCI Insight near-miss that is genuinely translational. Cell Press built this title for work that informs human health and medicine, so a paper with real clinical or disease consequence lands in scope. The bar is higher and the APC is steep, but the editorial appetite for bench-to-bedside framing is close to what JCI Insight wanted.

2. EMBO Molecular Medicine. The natural home when the contribution is the molecular mechanism of a disease, especially in a European research context. If JCI Insight found your paper "too molecular" or "too focused on one pathway," EMBO Molecular Medicine often values that exact depth, provided the disease link is explicit.

3. PNAS. A good move when the work is rigorous and complete but the translational narrative was the weak part. PNAS publishes biomedical research across all disease areas and rewards solid science without demanding the page-one clinical-relevance pitch JCI Insight screens for. Use it when the data are strong and the disease story is honestly preclinical.

4. eLife. Best for mechanism-first work where you value speed and transparency over a JIF. eLife moved to a reviewed-preprint model and no longer carries a current Journal Impact Factor, so weigh that against your career stage. The reviews and your responses publish alongside the paper, which suits authors confident in the science.

5. iScience. The broad-scope Cell Press landing spot for interdisciplinary or method-heavy biomedical work that does not need the clinical-investigation frame. If your real contribution is a technical advance, a dataset, or a cross-disciplinary finding, iScience frames it without forcing a translational wrapper.

6. The FASEB Journal. A solid fit when the paper is fundamentally an all-of-biology mechanism study, from molecular to organismal, that does not require the disease bridge JCI Insight wanted. It rewards rigorous biology across levels of organization without a translation gate.

7. JCI. The aspirational target, not a step down. If JCI Insight's reviewers signaled that the mechanism and disease relevance are both genuinely strong, the ASCI dual-journal track lets you aim at the flagship. Expect roughly a 10 percent acceptance rate and the most demanding mechanism-plus-disease bar on this list.

JCI Insight does not run a large cross-publisher transfer cascade the way some big commercial portfolios do. What it has is the ASCI dual-journal submission track, which links JCI Insight and its flagship sister JCI. Authors can be considered by both journals, and reviews can move between them during the process.

A manuscript reviewed for JCI can be expedited at JCI Insight on the strength of the existing reviews, and a JCI Insight paper with unexpectedly strong mechanism plus disease relevance can be steered toward JCI. The matching is editorial judgment within one society's two journals, not an algorithmic suggestion across thousands of titles.

That means a JCI Insight rejection usually leaves the next move in your hands: you choose the new target rather than accepting an automated offer.

Practical ladder by rejection reason:

• Desk-rejected for readership or field advance (too narrow, too incremental, no broad disease lesson)? Do not just resubmit unchanged to another high-bar venue. The readership problem follows the paper.

Reframe the abstract and figure sequence around the broader disease consequence, then pick the journal whose scope matches the real center of gravity: Cell Reports Medicine for translation, EMBO Molecular Medicine for molecular mechanism, FASEB Journal or iScience for mechanism without the clinical frame.

• Rejected for fit but with sound, complete science? This is the classic step-across case. PNAS or iScience is the next tier for rigorous work that does not need a clinical pitch.

If the science is genuinely strong on both mechanism and disease, use the dual-journal track and aim at JCI.

• Rejected after review for thin human-disease relevance, weak in vivo evidence, or a single-cohort claim? Fix it before resubmitting anywhere. Every serious clinical-investigation venue will raise the same point. Carry the strengthened human-disease bridge into the next submission rather than hoping a lower-bar journal waves it through.

In our pre-submission review work with JCI Insight manuscripts, the rejections we see most often cluster into four named patterns. Each is journal-specific and testable against your own manuscript, which is what makes them worth checking before you resubmit anywhere.

The specialty paper wearing a translational label. Across our JCI Insight pre-submission reviews, the single most common desk trigger is a figure sequence that behaves like a subspecialty paper while the abstract claims broad translational relevance. Figure 1 establishes a disease association, Figure 2 adds omics or mechanistic support, and the field-advance sentence appears only after several technical panels. The editor sees an incremental niche paper before seeing a JCI Insight paper.

The fix is structural, not cosmetic: move the broad disease consequence into the abstract and the first display item so the readership case is visible on the first read.

Mechanism built in models with human data appended. A second recurring pattern in the JCI Insight manuscripts we review is a mechanistic case carried almost entirely in cell lines or a rodent model, with human samples added late and doing no essential scientific work, a small retrospective cohort or a re-analysis of public data dropped in to justify a clinical-investigation venue.

Reviewers consistently flag the gap between the clinical framing and where the actual evidence lives. The fix is either real human-disease evidence that load-bears the claim, or an honest reframe as a mechanism paper for a journal like the FASEB Journal that does not require the bridge.

Single-cohort or under-controlled clinical claims. We see manuscripts where the headline human result rests on one cohort with no validation set, no matched control, or a statistical test that does not fit the design. A biomarker or treatment-response claim needs an independent cohort or at least a defensible internal control, plus a sample-size justification reviewers can check.

JCI Insight editors screen for under-supported clinical claims early, and reviewers reject when the analysis cannot separate the reported effect from noise. Check that every human-facing claim has appropriate controls and a test matched to your data structure.

Field-advance gap: solid but not new enough. The fourth pattern is a technically clean paper that confirms, in a new system, a mechanism already characterized in prior work. JCI Insight wants studies that meaningfully advance understanding or treatment of disease, not careful replication of established biology in one more context. When the central finding is "this known pathway also operates here," the desk filter removes it regardless of execution quality.

Read your own discussion and ask what a physician-scientist outside your subfield learns that they did not already know. If the answer is thin, the problem is novelty, and a lower-bar journal that does not gate on field advance, iScience or the FASEB Journal, is the more honest target.

Don't just resubmit the same file to the next high-bar journal. The fastest way to collect a second rejection is to send an unrevised manuscript to a venue that screens for the same thing JCI Insight did, and some manuscripts need real work, not a faster next submission. A desk rejection for readership or field advance is a framing problem you can fix by reordering the disease story and choosing the right-scope journal.

A post-review rejection for thin human-disease relevance, weak in vivo evidence, or an under-controlled cohort is a substance problem, and the same concerns will reappear at any serious clinical-investigation venue. Be honest about which one you got.

Two cases call for real work before resubmitting, not a faster next submission. First, if reviewers questioned whether the human-disease relevance is real, the manuscript needs genuine human evidence that does scientific work, not a cohort appended to justify the venue. Second, if the controls or statistics were challenged, new analysis, and sometimes a validation cohort, is the only fix.

Appealing is rarely worth it: a field-advance or readership rejection is an editorial judgment, not a factual error, and the appeal queue is slower than a clean resubmission to a better-fit journal. The exception is the dual-journal track, where a strong paper can legitimately move toward JCI rather than away from it.